NULIBRY™ (fosdenopterin) – Synthetic cPMP for MoCD Type A

TRUSELTIQ™ (high-dose infigratinib) – FGFR1-3 inhibitor for cholangiocarcinoma

Acoramidis (AG10) – TTR stabilizer for transthyretin amyloidosis (ATTR)

High-dose infigratinib – FGFR1-3 inhibitor for urothelial carcinoma (urinary tract and bladder cancer)

Low-dose infigratinib – FGFR1-3 inhibitor for achondroplasia

Encaleret – Ca sensing receptor antagonist for autosomal dominant hypocalcemia type 1 (ADH1)

BBP-418 – Glycosylation substrate pro-drug for limb-girdle muscular dystrophy 21 (LGMD2i)

BBP-589 – Recombinant collagen for recessive dystrophic epidermolysis bullosa (RDEB)

BBP-681 – Topical PI3Ka inhibitor for venous malformations (VMs), lymphatic malformations (LMs) and venolymphatic malformations (VLMs) associated with PIK3CA or TEK mutations

BBP-812 – AAV9 gene therapy for Canavan disease

BBP-398 – SHP2 inhibitor for tumors driven by RAS and receptor tyrosine kinase mutations

BBP-711 – Glycolate oxidase (GO) inhibitor for primary hyperoxaluria type 1 (PH1) and frequent stone formers

BBP-671 – PanK activator for pantothenate kinase-associated neurodegeneration (PKAN) and organic acidemias (OA)

Subramanian C, et al. Sci Transl Med. 2021 Sep 15;13(611):eabf5965. doi: 10.1126/scitranslmed.abf5965.

Sharma LK, et al. Nat Commun. 2018 Oct 23;9(1):4399. doi: 10.1038/s41467-018-06703-2. PMID: 30352999; PMCID: PMC6199309.

BBP-631 – AAV5 gene therapy for congenital adrenal hyperplasia (CAH)

BridgeBio

presentations & publications

BridgeBio is committed to letting science speak. Here we have gathered a selection of publications relevant to our programs.

 

links to an external site

indicates a PDF download